PlexBio Co

PlexBio Co CapEx Growth

The Year-over-Year CapEx Growth of PlexBio Co (6572.TWO) as of Nov 14, 2026 is -88.49 %. In the previous year, Year-over-Year CapEx Growth was 16.95 % — a change of -621.90% (lower).

CapEx Growth

-88.49 %

YoY

-621.90%

Last updated:

Year-over-Year CapEx Growth of PlexBio Co is 2025 -88.49 % . Year-over-Year CapEx Growth of PlexBio Co was 2024 16.95 % . It decreases by -621.90% lower compared to the previous year.

The PlexBio Co CapEx Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx Growth
Date
CapEx Growth
Jan 1, 2017
-82.85 TWD
Jan 1, 2018
-24.27 TWD
Jan 1, 2019
-100.00 TWD
Jan 1, 2021
78.73 TWD
Jan 1, 2022
-82.63 TWD
Jan 1, 2023
52.13 TWD
Jan 1, 2024
16.95 TWD
Jan 1, 2025
-88.49 TWD
The PlexBio Co CapEx Growth history
YEARCapEx GrowthYoY
-88.49 %-621.90%
16.95 %-67.48%
52.13 %-163.10%
-82.63 %-204.95%
78.73 %-178.73%
-100.00 %+311.96%
-24.27 %-70.70%
-82.85 %-301.87%
41.04 %-174.60%
-55.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PlexBio Co Stock analysis

What does PlexBio Co do? PlexBio Co., Ltd. generates revenue through the research, development, manufacture, and sale of medical testing equipment and reagents. The company's main products are diversified in-vitro diagnostic (IVD) medical devices, reagents, and other related equipment. They distribute these products domestically within Taiwan and to overseas markets including mainland China, America, and other areas. The firm targets healthcare providers and laboratories that require diagnostic tools for medical testing. PlexBio focuses on selling IVD medical devices and reagents to domestic and international clients. Their products are used in medical testing scenarios, serving both local and global healthcare sectors. The company's distribution channels cover Taiwan, mainland China, America, and other regions where diagnostic equipment is in demand. The business model relies on manufacturing and selling medical testing equipment and reagents to healthcare institutions. Their product portfolio includes IVD medical devices and reagents, which are sold across Taiwan, mainland China, America, and other markets. Revenue streams come from direct sales to healthcare facilities requiring diagnostic solutions. PlexBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PlexBio Co stock

Year-over-Year CapEx Growth of PlexBio Co is -88.49 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year CapEx Growth PlexBio Co since 2006 – with annual values, charts, and detailed analysis.

CapEx growth measures the percentage change in capital expenditures. Increasing CapEx can signal investment in future growth capacity.

To evaluate Year-over-Year CapEx Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year CapEx Growth.

Year-over-Year CapEx Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year CapEx Growth's PlexBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — PlexBio Co

All Key Metrics — PlexBio Co